Bavarian Nordic A/S (CPH: BAVA)
Denmark flag Denmark · Delayed Price · Currency is DKK
192.45
-0.60 (-0.31%)
Nov 21, 2024, 4:59 PM CET

Bavarian Nordic Company Description

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.

The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.

The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service.

It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally.

Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S
Bavarian Nordic logo
Country Denmark
Founded 1992
Industry Biotechnology
Sector Healthcare
Employees 1,379
CEO Paul Chaplin

Contact Details

Address:
Philip Heymans Alle 3
Hellerup, 2900
Denmark
Phone 45 33 26 83 83
Website bavarian-nordic.com

Stock Details

Ticker Symbol BAVA
Exchange Copenhagen Stock Exchange
Fiscal Year January - December
Reporting Currency DKK
ISIN Number DK0015998017
SIC Code 2836

Key Executives

Name Position
Dr. Paul John Chaplin MSc, Ph.D. Chief Executive Officer and President
Henrik Juuel M.Sc. Chief Financial Officer and Executive Vice President
Russell Thirsk M.Sc. Executive Vice President and Chief Operating Officer
Rolf Sass Sørensen Vice President of Investor Relations and Communications
Anu Helena Kerns M.Sc. Executive Vice President and Chief People and Sustainability Officer
Jean-Christophe May M.B.A., Pharm.D. Executive Vice President and Chief Commercial Officer